The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for ...

In a statement today, the company said it supports recent precautionary measures and that thorough investigations are needed ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The EMA now advises against using the drug for people aged over 65 after 17 serious adverse effects were recorded in this age ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...